Wipfli Financial Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wipfli Financial Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$122K	Buy	+611	New	+$117K	0.01%	638

Other funds holding ALNY

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wipfli Financial Advisors's ALNY Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2022: 611 shares worth $122K. The stake represents 0.01% of the portfolio and ranks #638 among its holdings.

496 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

Wipfli Financial Advisors held 611 shares of Alnylam Pharmaceuticals worth $122K as of Q3 2022.
Alnylam Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Alnylam Pharmaceuticals made up 0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #638 holding.
496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.